Venetoclax in combination with obinutuzumab in first line chronic lymphocytic leukemia in Argentina: A cost-effectiveness analysis
The aim of the study was to estimate the cost-effectiveness of VenG in the treatment of first-line unfit CLL patients in Argentina.
Guardado en:
| Autores principales: | , , , , |
|---|---|
| Formato: | Articulo |
| Lenguaje: | Inglés |
| Publicado: |
2022
|
| Materias: | |
| Acceso en línea: | http://sedici.unlp.edu.ar/handle/10915/156981 |
| Aporte de: |
| Sumario: | The aim of the study was to estimate the cost-effectiveness of VenG in the treatment of first-line unfit CLL patients in Argentina. |
|---|